Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps
On Tuesday, Embecta Corp (NASDAQ:EMBC) posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago.
周二，Embecta 公司（纳斯达克：EMBC）发布了第四季度调整后每股收益为45美分，超出市场共识的36美分，且较去年报告的59美分有所下降。
The company reported quarterly sales of $286.1 million, up 1.5% year over year, beating the consensus of $277 million.
该公司报告的季度销售额为28610万美元，同比增长1.5%，超出市场共识的27700万美元。
"We are pleased to report a strong fourth quarter and end to our fiscal year, as we once again delivered results that exceeded our expectations across key financial metrics...Additionally, the recent launch of our small-pack GLP-1 needles in Germany has gone well, and we are evaluating expanding into other markets," said Devdatt (Dev) Kurdikar, Chief Executive Officer of Embecta.
“我们很高兴能报告强劲的第四季度和我们的财年结束，因为我们再次在关键财务指标上交出了超出预期的业绩……此外，我们在德国推出的小包装GLP-1针头进展顺利，我们正在评估向其他市场扩展的可能性，”Embecta首席执行官Devdatt (Dev) Kurdikar说。
The Becton, Dickinson and Company (NYSE:BDX) spin-off announced that it decided to discontinue its insulin patch pump program and plans to initiate a restructuring plan.
贝克顿、迪金森和公司（纽交所：BDX）的分拆宣布决定停止其胰岛素贴片泵计划，并计划启动重组计划。
In July, Embecta, a manufacturer of disposable insulin pen needles and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson.
七月份，作为一次性胰岛素笔针和注射器的制造商，Embecta表示考虑在从医疗科技巨头贝克顿、迪金森分拆后，股价大幅下跌的情况下潜在出售。
"We intend to concentrate our resources on our core business and to prioritize our free cash flow towards paying down debt, which we expect will give us the financial flexibility needed for future investments," Kurdikar said.
Kurdikar表示：“我们打算集中资源于我们的核心业务，并优先使用我们的自由现金流来偿还债务，我们预计这将为未来的投资提供所需的财务灵活性。”
Embecta expects between $25 million and $30 million in pre-tax, cash charges for planned workforce reductions and other associated costs from the discontinuation of its patch pump program.
Embecta预计由于计划中的裁员和与停止其贴片泵计划相关的其他费用，将产生2500万到3000万美元的税前现金费用。
In total, Embecta expects between $35 million and $45 million in pre-tax charges in 2025 related to its restructuring plan. It anticipates completing the restructuring in the first half of 2025. Embecta projects annual cost savings of $60 million to $65 million from this restructuring.
总的来说，Embecta预计在2025年与其重组计划相关的税前费用在3500万到4500万美元之间。它预计将在2025年上半年完成重组。Embecta预计从此次重组中每年节省6000万到6500万美元的成本。
Given the organizational restructuring plan, the company has postponed its Analyst & Investor Day to Spring 2025.
鉴于组织重组计划，公司已将分析师与投资者日推迟至2025年春季。
Guidance: Embecta says that for the fiscal year 2025, excluding the Patch Pump program, revenues are expected to be $1.093 billion—$1.11 billion compared to a consensus of $1.12 billion, with an adjusted EPS of $2.70—$2.90 versus the consensus of $2.27.
指导意见：Embecta表示，除了Patch Pump项目外，2025财年的收入预期为10.93亿至11.1亿，与共识的11.2亿相比，调整后的每股收益预期为2.70至2.90美元，而共识为2.27美元。
Price Action: EMBC stock is up 33.5% at $19.23 at last check Tuesday.
价格走势：EMBC股票在周二最后检查时上涨了33.5%，报19.23美元。
